On 21 November 2025, Xuanzhu Biopharmaceutical Co., Ltd. (2575) released an announcement outlining its adoption of electronic dissemination for corporate communications in accordance with Rule 2.07 of The Stock Exchange of Hong Kong Limited’s Listing Rules. This follows the expansion of the paperless listing regime, which took effect on 31 December 2023.

The announcement states that English and Chinese versions of all future corporate communications, including annual reports, interim reports, meeting notices, listing documents, circulars, and proxy forms, will be available on both the company’s official website (www.xuanzhubio.com) and the HKExnews website (www.hkexnews.hk). Shareholders are advised to proactively monitor these websites for forthcoming publications.

Non-registered shareholders are encouraged to work with their respective intermediaries (such as banks, brokers, custodians, or nominees) to provide an up-to-date email address. A request to receive printed versions can be made by submitting the relevant reply form or by contacting the company’s H Share Registrar (Computershare Hong Kong Investor Services Limited), including a name, postal address, and the request for physical copies.